WO2012006368A3 - Compositions and methods for treating influenza - Google Patents
Compositions and methods for treating influenza Download PDFInfo
- Publication number
- WO2012006368A3 WO2012006368A3 PCT/US2011/043095 US2011043095W WO2012006368A3 WO 2012006368 A3 WO2012006368 A3 WO 2012006368A3 US 2011043095 W US2011043095 W US 2011043095W WO 2012006368 A3 WO2012006368 A3 WO 2012006368A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions
- methods
- treating influenza
- combination
- influenza
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010022000 influenza Diseases 0.000 title abstract 2
- 101710154606 Hemagglutinin Proteins 0.000 abstract 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 1
- 101710176177 Protein A56 Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000000185 hemagglutinin Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Compositions and methods useful for treating influenza that include an influenza virus hemagglutinin antigen in combination with lipid vesicles that include a non-ionic surfactant (NISVs) and/or in combination with a TLR-3 agonist adjuvant are descibed. The compositions remain potent even when they are not stored in a standard cold-chain system (i.e., they are thermostable).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36189910P | 2010-07-06 | 2010-07-06 | |
US61/361,899 | 2010-07-06 | ||
US201161431278P | 2011-01-10 | 2011-01-10 | |
US61/431,278 | 2011-01-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012006368A2 WO2012006368A2 (en) | 2012-01-12 |
WO2012006368A3 true WO2012006368A3 (en) | 2012-03-15 |
Family
ID=45441782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/043095 WO2012006368A2 (en) | 2010-07-06 | 2011-07-06 | Compositions and methods for treating influenza |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012006368A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011005772A1 (en) | 2009-07-06 | 2011-01-13 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
CA2767392C (en) | 2009-07-06 | 2017-03-14 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
MX342138B (en) | 2010-07-06 | 2016-09-14 | Variation Biotechnologies Inc | Compositions and methods for treating influenza. |
MX359103B (en) | 2011-01-13 | 2018-09-14 | Variation Biotechnologies Inc | Compositions and methods for treating viral infections. |
US20140356399A1 (en) | 2012-01-12 | 2014-12-04 | Variation Biotechnologies, Inc. | Compositions and methods for treating viral infections |
US20150079077A1 (en) * | 2012-01-27 | 2015-03-19 | Variation Biotechnologies, Inc. | Methods and compositions for therapeutic agents |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070264273A1 (en) * | 2003-06-18 | 2007-11-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Sphingoid polyalklamine conjugates, isomers and uses thereof |
US20100080844A1 (en) * | 2002-07-05 | 2010-04-01 | Andrew David Bacon | Method to enhance an immune response of nucleic acid vaccination |
-
2011
- 2011-07-06 WO PCT/US2011/043095 patent/WO2012006368A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100080844A1 (en) * | 2002-07-05 | 2010-04-01 | Andrew David Bacon | Method to enhance an immune response of nucleic acid vaccination |
US20070264273A1 (en) * | 2003-06-18 | 2007-11-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Sphingoid polyalklamine conjugates, isomers and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2012006368A2 (en) | 2012-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012006367A3 (en) | Compositions and methods for treating influenza | |
WO2012006368A3 (en) | Compositions and methods for treating influenza | |
WO2009001217A3 (en) | Low-additive influenza vaccines | |
WO2007098186A3 (en) | Adjuvant and vaccine compositions | |
CL2014002509A1 (en) | A composition comprising at least one source of boron and at least one source of silicon; product comprising substrate and composition; a method of providing a coated product; use of the composition. | |
MX2014008008A (en) | Solid compositions comprising an hcv inhibitor. | |
WO2013054199A3 (en) | Cmv antigens and uses thereof | |
WO2009114207A3 (en) | Replication-defective flavivirus vaccines and vaccine vectors | |
WO2010119343A8 (en) | Compositions for immunising against staphylococcus aureus | |
MX2010008799A (en) | Process for stabilizing an adjuvant containing vaccine composition. | |
WO2012100224A3 (en) | Preparation of metal-triazolate frameworks | |
WO2012177924A3 (en) | Influenza virus mutants and uses therefor | |
WO2011142858A3 (en) | Chlorotoxin variants, conjugates, and methods for their use | |
WO2009085025A3 (en) | System and method for sparql-query processing using parametrized-sparql-query in dbms-based systems | |
WO2012121547A3 (en) | Adhesive composition for a wafer processing film | |
EP2537822A3 (en) | Composite article including silicon oxycarbide layer | |
WO2008054481A3 (en) | Improved inactivated influenza virus compositions | |
WO2012080833A3 (en) | Controlled release dosage forms | |
CL2013001737A1 (en) | Cleaning composition comprising a non-ionic surfactant, inorganic base nanoparticles and a secondary surfactant; ready-to-use cleaning formulation comprising said composition; and composition for cleaning hard surfaces. | |
WO2013055877A3 (en) | Key with fixed key pin protruding from a key -cut surface | |
WO2009120380A3 (en) | Recombinant rhinovirus vectors | |
ECSP13013094A (en) | COLINA SALT CLEANING COMPOSITIONS | |
MX2015013832A (en) | Vaccine composition and method of use. | |
NZ606087A (en) | Influenza vaccine | |
WO2013111012A3 (en) | Methods and compositions for therapeutic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11804306 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11804306 Country of ref document: EP Kind code of ref document: A2 |